Literature DB >> 15650190

Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape.

Joshua N Leonard1, David V Schaffer.   

Abstract

Recently developed antiviral strategies based upon RNA interference (RNAi), which harnesses an innate cellular system for the targeted down-regulation of gene expression, appear highly promising and offer alternative approaches to conventional highly active antiretroviral therapy or efforts to develop an AIDS vaccine. However, RNAi is faced with several challenges that must be overcome to fully realize its promise. Specifically, it degrades target RNA in a highly sequence-specific manner and is thus susceptible to viral mutational escape, and there are also challenges in delivery systems to induce RNAi. To aid in the development of anti-human immunodeficiency virus (anti-HIV) RNAi therapies, we have developed a novel stochastic computational model that simulates in molecular-level detail the propagation of an HIV infection in cells expressing RNAi. The model provides quantitative predictions on how targeting multiple locations in the HIV genome, while keeping the overall RNAi strength constant, significantly improves efficacy. Furthermore, it demonstrates that delivery systems must be highly efficient to preclude leaving reservoirs of unprotected cells where the virus can propagate, mutate, and eventually overwhelm the entire system. It also predicts how therapeutic success depends upon a relationship between RNAi strength and delivery efficiency and uniformity. Finally, targeting an essential viral element, in this case the HIV TAR region, can be highly successful if the RNAi target sequence is correctly selected. In addition to providing specific predictions for how to optimize a clinical therapy, this system may also serve as a future tool for investigating more fundamental questions of viral evolution.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15650190      PMCID: PMC544124          DOI: 10.1128/JVI.79.3.1645-1654.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

Review 1.  RNAi: an ever-growing puzzle.

Authors:  Ahmet M Denli; Gregory J Hannon
Journal:  Trends Biochem Sci       Date:  2003-04       Impact factor: 13.807

2.  Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA.

Authors:  Michaela Scherr; Karin Battmer; Arnold Ganser; Matthias Eder
Journal:  Cell Cycle       Date:  2003 May-Jun       Impact factor: 4.534

3.  Allele-specific silencing of dominant disease genes.

Authors:  Victor M Miller; Haibin Xia; Ginger L Marrs; Cynthia M Gouvion; Gloria Lee; Beverly L Davidson; Henry L Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-02       Impact factor: 11.205

Review 4.  Mathematical models of HIV pathogenesis and treatment.

Authors:  Dominik Wodarz; Martin A Nowak
Journal:  Bioessays       Date:  2002-12       Impact factor: 4.345

5.  Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference.

Authors:  Maciej Wiznerowicz; Didier Trono
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

6.  Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs.

Authors:  Ming-Jie Li; Gerhard Bauer; Alessandro Michienzi; Jiing-Kuan Yee; Nan-Sook Lee; James Kim; Shirley Li; Daniela Castanotto; John Zaia; John J Rossi
Journal:  Mol Ther       Date:  2003-08       Impact factor: 11.454

7.  HIV-1 integration in the human genome favors active genes and local hotspots.

Authors:  Astrid R W Schröder; Paul Shinn; Huaming Chen; Charles Berry; Joseph R Ecker; Frederic Bushman
Journal:  Cell       Date:  2002-08-23       Impact factor: 41.582

8.  Generation of dendritic cells from lentiviral vector-transduced CD34+ cells from HIV+ donors.

Authors:  A Gruber; I Chen; K L Kuhen; J C Wheat; P Law; F Wong-Staal
Journal:  J Med Virol       Date:  2003-06       Impact factor: 2.327

9.  Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages.

Authors:  Akhil Banerjea; Ming-Jie Li; Gerhard Bauer; Leila Remling; Nan-Sook Lee; John Rossi; Ramesh Akkina
Journal:  Mol Ther       Date:  2003-07       Impact factor: 11.454

10.  Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection.

Authors:  Leor S Weinberger; David V Schaffer; Adam P Arkin
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

View more
  34 in total

1.  HIV develops indirect cross-resistance to combinatorial RNAi targeting two distinct and spatially distant sites.

Authors:  Priya S Shah; Nhung P Pham; David V Schaffer
Journal:  Mol Ther       Date:  2012-01-31       Impact factor: 11.454

2.  HIV-l and the microRNA-guided silencing pathway: an intricate and multifaceted encounter.

Authors:  Patrick Provost; Corinne Barat; Isabelle Plante; Michel J Tremblay
Journal:  Virus Res       Date:  2006-08-04       Impact factor: 3.303

Review 3.  Emergence of a complex relationship between HIV-1 and the microRNA pathway.

Authors:  Dominique L Ouellet; Isabelle Plante; Corinne Barat; Michel J Tremblay; Patrick Provost
Journal:  Methods Mol Biol       Date:  2009

4.  The impact of unprotected T cells in RNAi-based gene therapy for HIV-AIDS.

Authors:  Elena Herrera-Carrillo; Ying Poi Liu; Ben Berkhout
Journal:  Mol Ther       Date:  2013-12-12       Impact factor: 11.454

Review 5.  Selection of RNAi-based inhibitors for anti-HIV gene therapy.

Authors:  Stefanie A Knoepfel; Mireille Centlivre; Ying Poi Liu; Fatima Boutimah; Ben Berkhout
Journal:  World J Virol       Date:  2012-06-12

6.  HIV evades RNA interference directed at TAR by an indirect compensatory mechanism.

Authors:  Joshua N Leonard; Priya S Shah; John C Burnett; David V Schaffer
Journal:  Cell Host Microbe       Date:  2008-11-13       Impact factor: 21.023

7.  Emerging technologies for the genomic analysis of cancer.

Authors:  John Nemunaitis; Neil N Senzer
Journal:  F1000 Biol Rep       Date:  2009-05-08

8.  Deriving four functional anti-HIV siRNAs from a single Pol III-generated transcript comprising two adjacent long hairpin RNA precursors.

Authors:  Sheena Saayman; Patrick Arbuthnot; Marc S Weinberg
Journal:  Nucleic Acids Res       Date:  2010-06-04       Impact factor: 16.971

9.  96 shRNAs designed for maximal coverage of HIV-1 variants.

Authors:  Glen John McIntyre; Jennifer Lynne Groneman; Yi-Hsin Yu; Angel Jaramillo; Sylvie Shen; Tanya Lynn Applegate
Journal:  Retrovirology       Date:  2009-06-04       Impact factor: 4.602

10.  RNA polymerase III can drive polycistronic expression of functional interfering RNAs designed to resemble microRNAs.

Authors:  Lindsey L Snyder; Iqbal Ahmed; Laura F Steel
Journal:  Nucleic Acids Res       Date:  2009-08-13       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.